Please login to the form below

Mosquirix

This page shows the latest Mosquirix news and features for those working in and with pharma, biotech and healthcare.

Dosing of GSK's malaria vaccine due to start in 2018

GSK's vaccine – also known as Mosquirix – is considered to have limited efficacy, but the sheer scale of the public health problem posed by malaria in some areas of the world

Latest news

Malaria vaccine is first to provide 'sustained protection'

The results have been published in the journal Nature Medicine. That data looks pretty good when compared to trials of the Mosquirix malaria vaccine developed by GlaxoSmithKline (GSK) - which has already ... Mosquirix (formerly known as RTS, S) also
Shire and Baxalta drugs among CHMP's latest recommendations

Mosquirix outside the EU.
World first as CHMP backs GSK malaria vaccine Mosquirix

World first as CHMP backs GSK malaria vaccine Mosquirix. The EMA's scientific advisers recommend its useoutside Europe. ... The CHMP and GSK's biologics unit agreed measures to ensure the safety and effectiveness of Mosquirix is continuously monitored
GSK seeks approval for first malaria vaccine

Submits marketing application to European Medicines Agency
GSK’s 2011 sales dip but Witty confident for 2012

The remaining three products are skin cancer therapy BRAF, HIV/AIDS treatment dolutegravir and malaria vaccine Mosquirix.

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

GSK's malarial vaccine, Mosquirix which also contains Agenus’QS-21 Stimulon, was approved for use by the EMA in 2015.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Project / Account Manager (Medical Education): Salary TBC

Account Manager / Account Director: Competative

Account Director: £48, 000 - £60, 000

Director, Market Access / HEOR - North-West: Negotiable

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Medical/ Scientific Director: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Healthcare Communications Account Directors x 2: Salary TBC

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Production Manager – Healthcare Communications: DOE

Senior Medical Writer (Remote Working): Competitive Salary Offered

Account Director: Excellent benefits

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Senior Medical Writer: Great salary and benefits

Associate Director: £75, 000-90, 000

Account Manager / Senior Account Manager: 35, 000-40, 000

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Account Manager- Healthcare Advertising: Negotiable

Senior Account Executive, London, Medical Communications: Excellent package

Events Manager – Med Comms – Surrey: Salary TBC

Senior Medical Writer: Competitive Salary

New Business Director - PR: Competitive Salary and benefits

Associate Medical Director: Highly Competitive

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...